Search Result

Results for "

platelet aggregation induced by ADP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (1) Platelet-activating Factor Receptor (PAFR) (4) 5-HT Receptor (1) Adenosine Receptor (1) Adenylate Cyclase (2) Adrenergic Receptor (2) Apoptosis (3) Bacterial (2) Biochemical Assay Reagents (1) Cytochrome P450 (3) Drug Derivative (4) Drug Metabolite (3) Endogenous Metabolite (8) Histamine Receptor (1) HSP (2) Integrin (6) Isotope-Labeled Compounds (4) JNK (1) Keap1-Nrf2 (1) MMP (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) P-glycoprotein (1) P2X Receptor (1) P2Y Receptor (30) p38 MAPK (1) PANoptosis (1) PERK (1) Phosphodiesterase (PDE) (2) PPAR (1) Prostaglandin Receptor (5) Protease Activated Receptor (PAR) (1) Reference Standards (6) Src (2) Syk (1) Thrombin (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (59) Endocrinology (3) Infection (1) Inflammation/Immunology (7) Metabolic Disease (6) Neurological Disease (4)
Oligonucleotides:	Nucleotide Analogs (3) Adenine Nucleotide (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Platelet-activating Factor Receptor (PAFR) PINK1/Parkin PDGFR PARP Poly(ADP-ribose) Glycohydrolase (PARG) Arf Family GTPase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111557

YM-254890 Maximum Cited Publications 17 Publications Verification	P2Y Receptor	Cardiovascular Disease
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y₁ signal transduction pathway, with an IC₅₀ value below 0.6 μM .

HY-19638A

Cangrelor tetrasodium 4 Publications Verification AR-C69931MX tetrasodium	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 30 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-15284

Prasugrel 1 Publications Verification PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284A

Prasugrel hydrochloride 1 Publications Verification PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-134216

MAHMA NONOate 1 Publications Verification	Endogenous Metabolite NO Synthase	Cardiovascular Disease
MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .

HY-W009276

γ-Linolenic Acid methyl ester Methyl GLA	Apoptosis	Cancer
γ-Linolenic Acid methyl ester (Methyl GLA) is an esterified version of γ-Linolenic Acid (GLA), which is an ω-6 fatty acid, serves as melanoma cell proliferation inhibitors. γ-Linolenic Acid methyl ester inhibits ADP-induced blood platelet aggregation and induces apoptosis .

HY-108658

MRS2500 tetraammonium	P2Y Receptor	Cardiovascular Disease
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀ value of 0.95 nM. Antithrombotic activity .

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-78263

MNS 3 Publications Verification NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk NOD-like Receptor (NLR) Integrin PANoptosis	Neurological Disease Inflammation/Immunology Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .

HY-123669A

trans-R-138727	P2Y Receptor	Cardiovascular Disease
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .

HY-19638

Cangrelor AR-C69931MX	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .

HY-N5021

Anhydrosafflor yellow B AHSYB	Others	Neurological Disease
Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H₂O₂-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .

HY-164090

Adenosine 3'-phosphate 5'-phosphosulfate	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-149454

P2Y1/P2Y12 antagonist-1 1 Publications Verification	P2Y Receptor	Cancer
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC₅₀ of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.

HY-W010918R

Adenosine 5'-diphosphate (Standard) Adenosine diphosphate (Standard); ADP (Standard)	Reference Standards Endogenous Metabolite	Others
Adenosine 5'-diphosphate (Standard) is the analytical standard of Adenosine 5'-diphosphate. This product is intended for research and analytical applications. Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors. In Vitro: Adenosine 5'-diphosphate consists of the pyrophosphate group, the pentose sugar ribose, and the nucleobase adenine. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. ADP is converted back to ATP by ATP synthases. ATP is an important energy transfer molecule in cells. Adenosine 5'-diphosphate is utilized in a wide number of cellular processes, including respiration, biosynthetic reactions, motility, and cell division.

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-N7614

Anemarrhenasaponin A2 1 Publications Verification Schidigerasaponin F2; Timosaponin AII	Others	Cardiovascular Disease
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .

HY-119860

Ataprost ONO 41483	Drug Derivative	Cardiovascular Disease
Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm .

HY-Y1094

[Rh(cod)Cl]2 Chloro(1,5-cyclooctadiene)rhodium(I) dimer	Biochemical Assay Reagents	Cardiovascular Disease
[Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) is a rhodium (I) organometallic dimer complex. [Rh(cod)Cl]2 can inhibit platelet-activating factor-mediated platelet aggregation with IC₅₀ values of 5.2 and 43.3 μM in washed rabbit platelets and human platelet-rich plasmas. [Rh(cod)Cl]2 also can inhibit thrombin-, ADP (HY-W010918)- and collagen-induced aggregation with IC₅₀ values of 16.7, 162 and 69.8 μM. [Rh(cod)Cl]2 can be used for the research of cardiovascular disease, such as thrombosis .

HY-N9422

Adenosine 3'-phosphate 5'-phosphosulfate triethylamine	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-N1717

2-Acetylbenzoic acid	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak **platelet aggregation** inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .

HY-108633

BYK 49187	PARP	Cancer
AR-C66096 (FPL 66096) tetrasodium is a selective platelet P2Y_T receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism .

HY-113096

Prostaglandin D1 PGD1	Endogenous Metabolite	Metabolic Disease
Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .

HY-134556

2'-Hydroxyflavanone	Apoptosis	Inflammation/Immunology Cancer
2'-Hydroxyflavanone is a flavanone that can inhibit cancer cell proliferation, induce apoptosis, and reduce inflammation. 2'-Hydroxyflavanone shows inhibitory effect on **platelet aggregation** caused by two inducers with IC₅₀s 47.8 μM arachidonic acid (AA) and 147.2 μM aenosine diphosphate (ADP) .

HY-19638AR

Cangrelor tetrasodium (Standard) AR-C69931MX tetrasodium (Standard)	P2Y Receptor Reference Standards	Cardiovascular Disease Inflammation/Immunology
Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-148300

AR-C66096	P2Y Receptor	Cardiovascular Disease
AR-C66096 is a potent and selective antagonist of the Gi-coupled P2Y12 receptor. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate	P2Y Receptor	Cardiovascular Disease
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-175675

P2Y1 antagonist 4	P2Y Receptor Keap1-Nrf2	Cardiovascular Disease Neurological Disease
P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca ²⁺ increase (IC₅₀ = 1.95 μM) and platelet aggregation (IC₅₀ = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .

HY-175986

IP receptor agonist 1	Prostaglandin Receptor	Inflammation/Immunology
IP receptor agonist 1 (compound 6c-14S) is an orally active I prostanoid receptor agonist, with an IC₅₀ of 0.15 μM for inhibiting platelet aggregation induced by ADP (HY-W010918,300 μM) in rabbit platelet-rich plasma. IP receptor agonist 1 can be used for study of Pulmonary arterial hypertension .

HY-P1702

GR83895	Integrin	Others
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM) .

HY-N14932

Aggreceride A	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Aggreceride A is a **platelet aggregation** inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-N14933

Aggreceride B	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Aggreceride B is a **platelet aggregation** inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-N14934

Aggreceride C	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Aggreceride C is a **platelet aggregation** inhibitor. Aggreceride C shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-116850

Oxagrelate EG626; Phthalazinol; SC-32840	Phosphodiesterase (PDE)	Neurological Disease
Oxagrelate is a specific inhibitor of cyclic adenosine monophosphate phosphodiesterase and exhibits concentration-dependent inhibition of collagen- and ADP-induced platelet aggregation in vitro .

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-176060

Platelet aggregation-IN-3	Histamine Receptor Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease Cancer
Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis .

HY-W419570

(Rac)-BX 048	P2Y Receptor	Cardiovascular Disease
(Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC₅₀ of 15 μM) .

HY-N13135

Kadsutherin G	Others	Cardiovascular Disease
Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .

HY-113113

13,14-Dihydro PGE1 13,14-Dihydroprostaglandin E1	Endogenous Metabolite	Metabolic Disease
13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

HY-173207

Antiplatelet agent 3	Thrombin	Cardiovascular Disease
Antiplatelet agent 3 (Compound K-10) is a compound with anti-platelet aggregation activity. The IC₅₀ values for platelet aggregation induced by *ADP, AA and COL* are 2.55, 3.22 and 2.09 mg/mL, respectively. Antiplatelet agent 3 is expected to be used in the research of cardiovascular diseases .

HY-167686

Variabilin Homopisatin	Integrin	Cardiovascular Disease
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and **platelet aggregation** inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

HY-15284S1

Prasugrel-d3 PCR 4099-d₃	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5 PCR 4099-d₅	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-122048

AR-C67085 AR-C67085MX; PSB 0413; FPL 67085	P2Y Receptor	Cardiovascular Disease
AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P_2T receptor antagonist with an pIC₅₀ value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation .

HY-N13134

Kadsutherin F	Others	Cardiovascular Disease
Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .

HY-113723

MRS2298	P2Y Receptor	Cardiovascular Disease
MRS2298? is a potent acyclic P2Y1 receptor antagonist with a K_i of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC₅₀ of 62.8 nM. MRS2298 inhibits Ca ²⁺ rise in platelets with an IC₅₀ of 810 nM .

HY-131776A

2-Chloro-ADP sodium 2-Chloroadenosine 5′-diphosphate sodium	Adenylate Cyclase HSP	Cardiovascular Disease
2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sodium is a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP sodium inhibits mortalin nucleotide-binding domain (NBD) with a K_i of 45.05 μM .

HY-112658

p-Iodoclonidine hydrochloride	Adrenergic Receptor Adenosine Receptor	Endocrinology
p-Iodoclonidine hydrochloride is a partial agonist of α2-adrenergic receptor. p-Iodoclonidine hydrochloride also has minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, and potentiates ADP induced platelet aggregation with an EC₅₀ of 1.5 μM .

HY-15284AR

Prasugrel hydrochloride (Standard) PCR 4099 hydrochloride (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

Cat. No.	Product Name	Type

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Cat. No.	Product Name	Target	Research Area

HY-P1702

GR83895	Integrin	Others
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM) .

HY-P5764

TRAP-14 amide	Protease Activated Receptor (PAR) Integrin MMP	Cardiovascular Disease
TRAP-14 amide, a proteinase activated receptor (PAR)-activating peptide, is a PAR agonist with an EC₅₀ of 24 μM. TRAP-14 amide significantly induces platelet aggregation through *ADP- and MMP-2-dependent pathways with Aspirin (HY-14654)-insensitivity. TRAP-14 amide also effectively increases glycoprotein (GP) Ib* and GPIIb/IIIa surface expression and ADP release .

HY-P11467

Gy-CATH	Bacterial p38 MAPK NF-κB PERK JNK	Cardiovascular Disease Infection
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111557

YM-254890 Maximum Cited Publications 17 Publications Verification	Cardiovascular Disease Natural Products Microorganisms Classification of Application Fields Disease Research Fields Source Classification	P2Y Receptor
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y₁ signal transduction pathway, with an IC₅₀ value below 0.6 μM .

HY-134216

MAHMA NONOate 1 Publications Verification	Cardiovascular Disease Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NO Synthase
MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .

HY-N5021

Anhydrosafflor yellow B AHSYB	Quinones Simple Phenylpropanols Carthamus tinctorius L. Phenols Polyphenols Benzene Quinones Phenylpropanoids Plants Compositae Source Classification	Others
Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H₂O₂-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .

HY-W010918R

Adenosine 5'-diphosphate (Standard) Adenosine diphosphate (Standard); ADP (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Source Classification	Reference Standards Endogenous Metabolite
Adenosine 5'-diphosphate (Standard) is the analytical standard of Adenosine 5'-diphosphate. This product is intended for research and analytical applications. Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors. In Vitro: Adenosine 5'-diphosphate consists of the pyrophosphate group, the pentose sugar ribose, and the nucleobase adenine. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. ADP is converted back to ATP by ATP synthases. ATP is an important energy transfer molecule in cells. Adenosine 5'-diphosphate is utilized in a wide number of cellular processes, including respiration, biosynthetic reactions, motility, and cell division.

HY-N7614

Anemarrhenasaponin A2 1 Publications Verification Schidigerasaponin F2; Timosaponin AII	Cardiovascular Disease Liliaceae Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Disease Research Fields Steroids Source Classification	Others
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .

HY-N1717

2-Acetylbenzoic acid	Natural Products Ketones, Aldehydes, Acids Impatiens balsamina Linn. Balsaminaceae Plants Source Classification	Platelet-activating Factor Receptor (PAFR)
2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak **platelet aggregation** inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .

HY-134556

2'-Hydroxyflavanone	Flavonoids Mimosa pudica Linn. Leguminosae Flavonones Plants Source Classification	Apoptosis
2'-Hydroxyflavanone is a flavanone that can inhibit cancer cell proliferation, induce apoptosis, and reduce inflammation. 2'-Hydroxyflavanone shows inhibitory effect on **platelet aggregation** caused by two inducers with IC₅₀s 47.8 μM arachidonic acid (AA) and 147.2 μM aenosine diphosphate (ADP) .

HY-N14932

Aggreceride A	Natural Products Microorganisms Source Classification	Platelet-activating Factor Receptor (PAFR)
Aggreceride A is a **platelet aggregation** inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-N14933

Aggreceride B	Natural Products Microorganisms Source Classification	Platelet-activating Factor Receptor (PAFR)
Aggreceride B is a **platelet aggregation** inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-N14934

Aggreceride C	Natural Products Microorganisms Source Classification	Platelet-activating Factor Receptor (PAFR)
Aggreceride C is a **platelet aggregation** inhibitor. Aggreceride C shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .

HY-N13135

Kadsutherin G	Kadsura heteroclita (Roxb.) Craib Lignans Phenylpropanoids Plants Schisandraceae Source Classification	Others
Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .

HY-167686

Variabilin Homopisatin	Structural Classification Natural Products Plants Dalbergia variabilis Fabaceae Source Classification	Integrin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and **platelet aggregation** inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

HY-N13134

Kadsutherin F	Kadsura heteroclita (Roxb.) Craib Lignans Phenylpropanoids Plants Schisandraceae Source Classification	Others
Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .

HY-124371

Amentoflavone hexaacetate	Flavonoids Viburnaceae Plants Biflavones Viburnum lantana L. Source Classification	Phosphodiesterase (PDE)
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .

HY-N4266

Vinaginsenoside R8	Cardiovascular Disease Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Others
Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC₅₀=25.18 μM) .

HY-N12070

11-O-β-D-glucopyranosyl thamnosmonin	Coumarins Phenylpropanoids Cynara scolymus L. Umbelliferae Plants Source Classification	Others
11-O-β-D-glucopyranosyl thamnosmonin, a coumarin glucosides, can be isolated from the roots of Angelica apaensis. 11-O-β-D-glucopyranosyl thamnosmonin has weak inhibitory activity on the aggregation of rabbit platelets induced by PAF, AA, and ADP .

HY-N19129

Macrostemonoside E	Structural Classification Natural Products Allium macrostemon Bunge Plants Amaryllidaceae Source Classification	Others
Macrostemonoside E is a steroidal glycoside present in Allium macrostemon Bunge, which inhibits ADP-induced aggregation of human platelets in vitro (IC₅₀=0.417 mM) .

HY-N17403

Decuroside IV	Structural Classification Artemisia judaica L. Flavonoids Flavonones Umbelliferae Plants Source Classification	Drug Derivative
Decuroside IV is a coumarin-glycoside inhibitor that can be found in the roots of Peucedanum decursivum Maxim. Decuroside IV inhibits secondary wave aggregation of human platelets induced by *ADP* .

HY-N17941

19-Anhydro-4-epirotungenic acid	Aquifoliaceae Structural Classification Terpenoids Parameria laevigata (Juss.) Moldenke Plants Pentacyclic Triterpenoids Source Classification	Others
19-Anhydro-4-epirotungenic acid is a triterpenoid compound that can be isolated from the bark of Ilex rotunda Thunb. 19-Anhydro-4-epirotungenic acid shows no activity against *ADP*-induced platelet aggregation .

HY-N17826

YM-254891	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite
YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .

Cat. No.	Product Name	Chemical Structure

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-113113S

13,14-Dihydro PGE1-d4
13,14-Dihydro PGE1-d₄ (13,14-Dihydroprostaglandin E1-d₄) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

HY-113096S

Prostaglandin D1-d4
Prostaglandin D1-d₄ (PGD1-d₄) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

Cat. No.	Product Name		Classification

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-164090

Adenosine 3'-phosphate 5'-phosphosulfate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

platelet aggregation induced by ADP

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products